MRSA Detection : 6 Hours
Group B Strep Detection : ± 6 Hours
E. coli Detection : 4 Hours
Anthrax Detection : ± 1 Hour
RAPID DETECTION OF VIABLE MICROORGANISMS
NanoLogix® NanoLogix BNP Petri-based sandwiched-membrane kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology. NanoLogix FlatPack packaging allows for an extended shelf-life for both our Petri plates and our BNP kits that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix Petri plates containing TSA media in FlatPacks® have maintained viability for nutrient and moisture levels for over three years in cold storage and over two years at room temperature (RT), as compared to 3-1/2 months of useable shelf life for competitive products that require refrigeration. Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures. All of the Petri plates and BNP Petri kits NanoLogix produces are packaged in FlatPack packaging to ensure the longest useable shelf life, with most of the FlatPacks we produce undergoing a further electron-beam (e-beam) processing step to provide customers with the best product for their use with an extremely long shelf life.
NanoLogix®, Inc. is a biotechnology company specializing in live cell, rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, national defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
Stock Symbol: NNLX
COMPANY OPERATIONS SUMMARY
April 30, 2013
The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.
The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.
In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.
Scholarship and Research on NanoLogix Technologies
In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. http://www.hindawi.com/journals/idog/2013/367935/
New License and Patents
The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack® packaging technology, to which NanoLogix has an exclusive license. The FlatPack® technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack® Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco
In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.
In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.
07.08.14 00:05 Nanologix® News wire:
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
NanoLogix Inc. (NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link
The European Patent Office has informed our London and US Patent Law firms that our European application for the NanoLogix BNP sandwiched-membrane Petri based detection technology has received an allowance for grant under the European Patent Convention. The patent will cover up to 38 member countries, dependent upon NanoLogix’s election, and significantly enhances the NanoLogix Patent Portfolio. The BNP technology received patent grants in 2013 in both Japan and Russia and is currently patent pending in the United States.
At the American Society for Microbiology (ASM) annual meeting in late May, NanoLogix's display booth was visited by NASA. Upon viewing the NanoLogix Petri plates vacuum packed in nitrogen-charged FlatPacks, the following comment was made: “This is exactly what we’ve been looking for. We’re sending these up there,” referring to the International Space Station (ISS). In early June, at NASA’s request, NanoLogix supplied NASA with a number of Petri and BNP FlatPacks for their use. The company is currently awaiting further information from NASA and will release additional news as appropriate. The qualities that are of interest to NASA are the robust nature of the Petri dishes packaged in the patented FlatPack with enhanced durability and resistance to breakage, coupled with the long term room-temperature shelf life of at least two years, compared to the competition’s shelf life of 3-1/2 months refrigerated.
06.27.14 11:15 Nanologix® News:
Nanologix granted an European patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the BNP has been granted as a European Patent under the European Patent Convention. The 38 member states where this patent applies are: Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Turkey, Bulgaria, Czech Republic, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Croatia, Norway, Former Yugoslav Republic of Macedonia, San Marino, Albania, and Serbia. With the EU Patent grant, NanoLogix is electing to file for national patent issuance in the majority of the covered countries with some exceptions. This BNP patent grant joins the NanoLogix portfolio of patents for the BNP granted in Japan and Russia, and when each member state patent is issued to NanoLogix will dramatically increase the number of granted patents in our portfolio.
06.04.14 05:05 Nanologix® News:
YSU business students learn by doing
NanoLogix is pleased to have been mentioned in a news update from Youngstown State University's Williamson College of Business Administration. The update focused upon the participation of seven area companies that worked with students on their Exporting Course projects for assessing international marketing potential. The assessments were performed utilizing a powerful marketing resource database available through the University and the State of Ohio. The management and staff of NanoLogix, as a member of the local business community and as a current exporter to a number of countries, view participation in educational projects such as this as part of their duty to that community. We are pleased to have been able to contribute to the education of students about to enter their business careers. more>>>
05.20.14 01:05 Nanologix® NewsWire: Nanologix Exhibits at ASM Annual Meeting in Boston and welcomes VP for Sales and Marketing Read more>>>
04.14.14 00:05 Nanologix® News: NanoLogix's new N-Assay rapid test discussed in article by Dr. Jonathan Faro in latest issue of Med Lab Observer Read more>>>
01.27.14 00:05 Nanologix® News: State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements Read more>>>
12.04.13 12:02 Nanologix® News: Announces additional product offerings with E-Beam sterilization process - NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region Read more>>>
06.21.13 NanoLogix BNP Instructional Video
06.11.13 02:31 Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>
NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>
04.02.13 10:29 Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..
03.13.13 10:29 Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. Read more>>>
11.09.12 Nanologix® News: NanoLogix Subject of EPA Featured News article. Read more>>
6.13.12 Health News Texas: Texas Health Science Center-Huston instrumental in New NanoLogix Technology Read the article>>
SIGN UP FOR eNEWS
Feb 11, 2015:
NanoLogix is pleased to announce receipt of notification of allowance and/or granting of patents in the US and internationally for USA: BNF for use with Antibodies and Aptamers USA: N-Assay Rapid Detection Technology China: FlatPack Packaging New Zealand: FlatPack Packaging The allowance and upcoming grants of patents significantly strengthen the position of the Company's intellectual property both domestically and internationally
Jan 14, 2015:
NanoLogix is pleased to share the following information: In recent and ongoing work, researchers in the United States have confirmed the potential efficacy of NanoLogix's N-Assay as a rapid indicator for the presence of the current-threat strain of the Ebola virus, EBOV. The research demonstrates a sub-three hour result at present. Researchers are working to refine the test and reduce time-to-detection to facilitate the N-Assay's use as a Point of Care (POC) diagnostic for hemorrhagic and other viruses.
Nov 4, 2014:
Ebola epidemic spurs hunt for new, faster tests more>>>
Oct 14, 2014:
NanoLogix Technology Being Configured For Rapid Ebola Virus Detection more>>>
Sep 29, 2014:
NanoLogix Technology Cited In UNITAID Annual Report On TB, Through The World Health Organization more>>>
Sep 19, 2014:
NanoLogix is very pleased to announce that The Ohio State University has issued a Purchase Order (PO) to NanoLogix Incorporated to supply the University with the following:
- Gel culture media
- Cell culture supplements
- Biochemical reagents
- Cell preservation/growth supplies
This PO runs from September 17, 2014 to June 30, 2015 and is a blanket Purchase Order for lab supplies.
Aug 6, 2014:
Dr. Sebastian Faro's presentation video on NanoLogix BNF and N-Assay technologies more>>>
Aug 4, 2014:
Third party tests result surpasses Nanologix's competition
NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab. more>>>